Domanda e risposta
Si avvertono gli utenti del sito che le risposte dell'A.I.I.Re., gli interventi nel blog e nel forum sono di natura amichevole e non sostitutivi di una consulenza professionale diretta.
consigli per la sclerosi multipla vitamina D e melatonina
Risposta a: Cinzia - 30/05/2013
Salve , ho 25 anni e soffro di sclerosi multipla , la stanchezza che ti crea è devastante ... i dottori spesso si preoccupano solo dei segni evidenti lasciando da parte la difficoltà quotidiana la mancanza di energie, magari consigli su alimenti che possano essere migliori o altro.
Risposta:
Cara Cinzia, parrebbe che la vitamina D insieme alla melatonina agisca favorevolmente nella neuromodulazione nei pazienti con sclerosi multipla. Non se ne parla, ma l'articolo qui sotto è un contributo scientifico importantissimo del maggio 2013. Sono come sai uno studioso della magica vitamina D e della malatonina essenziali nelle terapie di prevenzione, nelle cure dei disturbi autoimmunitari e nell'anti-aging.
Buona Vita Angelo Bona
Brain Behav Immun. 2013 May 7. pii: S0889-1591(13)00178-5. doi: 10.1016/j.bbi.2013.04.010. [Epub ahead of print]
The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis.
Golan D, Staun-Ram E, Glass-Marmor L, Lavi I, Rozenberg O, Dishon S, Barak M, Ish-Shalom S, Miller A.
Source
Division of Neuroimmunology & Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel; Department of Neurology, Carmel Medical Center, Haifa, Israel.
Abstract
BACKGROUND:
Multiple sclerosis (MS) incidence is higher in geographic regions with less sunlight exposure. Both vitamin D and melatonin are essential mediators of the effect of sunlight in health, and as such are candidates to play a key role in MS. We hypothesized that vitamin D and melatonin may have related influences in patients with MS.
METHODS:
In a randomized, double blind study of 40 IFN-β treated MS patients, 21 patients were assigned to 800IU of vitamin D3 per day (low dose), while 19 patients received 4,370IU vitamin D3 per day (high dose) for one year. Serum 25-hydroxy-vitamin-D (25-OH-D) and nighttime urine melatonin metabolite, 6-sulphatoxy-melatonin (6-SMT), were measured at baseline, 3months and 1year from enrolment.
RESULTS:
After 3months supplementation, 25-OH-D levels increased and nighttime melatonin secretion decreased significantly in the high dose group, but not in the low dose group. After 1year, a decrease in 25-OH-D levels, accompanied by an increase of urine nighttime 6-SMT were observed in the high dose group. Percent change in serum 25-OH-D was significantly and negatively correlated with percent change in urine 6-SMT after 3months and between 3months to 1year. 25-OH-D levels by the end of the study were significantly and negatively correlated to BMI.
CONCLUSIONS:
Melatonin secretion is negatively correlated with alterations in serum 25-OH-D in IFN-β treated patients with MS. The finding suggests that melatonin should be considered as a potential mediator of vitamin D neuro-immunomodulatory effects in patients with MS.
